MX2021011224A - Un método para tratar la hipertensión arterial pulmonar y la hipertensión arterial pulmonar asociada y pauta posológica diaria. - Google Patents
Un método para tratar la hipertensión arterial pulmonar y la hipertensión arterial pulmonar asociada y pauta posológica diaria.Info
- Publication number
- MX2021011224A MX2021011224A MX2021011224A MX2021011224A MX2021011224A MX 2021011224 A MX2021011224 A MX 2021011224A MX 2021011224 A MX2021011224 A MX 2021011224A MX 2021011224 A MX2021011224 A MX 2021011224A MX 2021011224 A MX2021011224 A MX 2021011224A
- Authority
- MX
- Mexico
- Prior art keywords
- arterial hypertension
- pulmonary arterial
- treating
- patient
- apah
- Prior art date
Links
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 title abstract 7
- 150000003839 salts Chemical class 0.000 abstract 2
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 abstract 1
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- TZSZZENYCISATO-WIOPSUGQSA-N rodatristat Chemical compound CCOC(=O)[C@@H]1CC2(CN1)CCN(CC2)c1cc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)nc(N)n1 TZSZZENYCISATO-WIOPSUGQSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962819162P | 2019-03-15 | 2019-03-15 | |
| PCT/IB2020/000177 WO2020188352A1 (en) | 2019-03-15 | 2020-03-13 | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021011224A true MX2021011224A (es) | 2021-12-10 |
Family
ID=71092560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021011224A MX2021011224A (es) | 2019-03-15 | 2020-03-13 | Un método para tratar la hipertensión arterial pulmonar y la hipertensión arterial pulmonar asociada y pauta posológica diaria. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11576915B2 (https=) |
| EP (1) | EP3938043A1 (https=) |
| JP (1) | JP2022525202A (https=) |
| KR (1) | KR20210139293A (https=) |
| CN (1) | CN113784717A (https=) |
| AU (1) | AU2020244278A1 (https=) |
| CA (1) | CA3133589A1 (https=) |
| MX (1) | MX2021011224A (https=) |
| WO (1) | WO2020188352A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11413287B2 (en) * | 2018-11-16 | 2022-08-16 | Altavant Sciences Gmbh | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension |
| MX2021009055A (es) * | 2019-01-30 | 2021-10-22 | Altavant Sciences Gmbh | Pauta posológica y método para tratar la hipertensión arterial pulmonar con rodatristat etilo. |
| AU2020244278A1 (en) | 2019-03-15 | 2021-09-30 | Altavant Sciences Gmbh | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
| WO2023062595A1 (en) | 2021-10-14 | 2023-04-20 | Altavant Sciences Gmbh | Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7875622B2 (en) * | 2007-07-11 | 2011-01-25 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for treating pulmonary hypertension and related diseases and disorders |
| UA119247C2 (uk) * | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
| US9399741B2 (en) | 2013-10-09 | 2016-07-26 | Uop Llc | Methods and apparatuses for desulfurizing hydrocarbon streams |
| CA3119912A1 (en) * | 2018-11-14 | 2020-05-22 | Altavant Sciences Gmbh | A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (tph1) for treating diseases or disorders associated with peripheral serotonin |
| US11413287B2 (en) | 2018-11-16 | 2022-08-16 | Altavant Sciences Gmbh | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension |
| WO2020128614A1 (en) | 2018-12-17 | 2020-06-25 | Altavant Sciences Gmbh | Method for treating interstital lung disease |
| WO2020128608A1 (en) | 2018-12-17 | 2020-06-25 | Altavant Sciences Gmbh | Compound for use in a method for treating sarcoidosis-associated pulmonary hypertension |
| MX2021009055A (es) | 2019-01-30 | 2021-10-22 | Altavant Sciences Gmbh | Pauta posológica y método para tratar la hipertensión arterial pulmonar con rodatristat etilo. |
| AU2020244278A1 (en) | 2019-03-15 | 2021-09-30 | Altavant Sciences Gmbh | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
-
2020
- 2020-03-13 AU AU2020244278A patent/AU2020244278A1/en not_active Abandoned
- 2020-03-13 WO PCT/IB2020/000177 patent/WO2020188352A1/en not_active Ceased
- 2020-03-13 CN CN202080033296.0A patent/CN113784717A/zh active Pending
- 2020-03-13 EP EP20732658.8A patent/EP3938043A1/en not_active Withdrawn
- 2020-03-13 JP JP2021555469A patent/JP2022525202A/ja active Pending
- 2020-03-13 KR KR1020217031156A patent/KR20210139293A/ko not_active Abandoned
- 2020-03-13 US US16/818,236 patent/US11576915B2/en active Active
- 2020-03-13 MX MX2021011224A patent/MX2021011224A/es unknown
- 2020-03-13 CA CA3133589A patent/CA3133589A1/en active Pending
-
2023
- 2023-01-04 US US18/149,992 patent/US20240024316A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3938043A1 (en) | 2022-01-19 |
| CA3133589A1 (en) | 2020-09-24 |
| US20200289510A1 (en) | 2020-09-17 |
| WO2020188352A1 (en) | 2020-09-24 |
| CN113784717A (zh) | 2021-12-10 |
| KR20210139293A (ko) | 2021-11-22 |
| US11576915B2 (en) | 2023-02-14 |
| US20240024316A1 (en) | 2024-01-25 |
| AU2020244278A1 (en) | 2021-09-30 |
| JP2022525202A (ja) | 2022-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021011224A (es) | Un método para tratar la hipertensión arterial pulmonar y la hipertensión arterial pulmonar asociada y pauta posológica diaria. | |
| MX2008013578A (es) | Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k). | |
| GB0423653D0 (en) | Pharmaceutical compounds | |
| CA2549801A1 (en) | Use of treprostinil to improve kidney functions | |
| IL166413A0 (en) | Use of and some novel imidazopyridines | |
| WO2020157577A8 (en) | A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl | |
| WO2001039762A3 (en) | Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system | |
| TN2009000444A1 (en) | Combination therapy with a compound acting as a plateletadp receptor inhibitor | |
| NZ592608A (en) | Benzoxazole kinase inhibitors and methods of use | |
| JP2002523370A5 (https=) | ||
| AU2020278236A8 (en) | Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor | |
| WO2010107807A3 (en) | Compounds for treating inflammation and pain | |
| WO2007149283B1 (en) | Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload | |
| EP4599894A3 (en) | Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor | |
| MX2022008342A (es) | Metodos para tratar afecciones relacionadas con el receptor de s1p1. | |
| EP1594885B8 (de) | Medikament zur wachstumsinhibierung von tumoren | |
| SG141358A1 (en) | Treatment of psychiatric patients with reduced heptaic function with paliperidone | |
| WO2020219645A3 (en) | Methods for reducing the weight loss or increasing the weight of a feline in need thereof | |
| MX2022006083A (es) | Metodos para tratar afecciones relacionadas con el receptor s1p1. | |
| MX2023012039A (es) | Compuestos bicíclicos fusionados sustituidos como inhibidores de parp y uso de estos. | |
| RU2015119377A (ru) | Лекарственные формы леводопы для быстрого купирования болезни паркинсона | |
| NZ587941A (en) | Methods to inhibit tumor cell growth by using lansoprazole | |
| WO2020128614A8 (en) | Method for treating interstital lung disease | |
| MX2025005154A (es) | Formulaciones orales compactables de ibutamoren. | |
| TW200503666A (en) | Treatment of type 1 diabetes with pde5 inhibitors |